Why did PMCB's EPS remain flat in recent quarters?

The EPS of PMCB has not remained flat in recent quarters. It experienced a significant increase from $0.26 in Q3 2024 to $1.83 in Q2 2025, as shown in the diluted EPS in recent quarters. However, it is important to note that the EPS of PMCB turned negative from Q4 2024 to Q1 2025, as shown in the diluted EPS in recent quarters. The fluctuation in EPS can be attributed to various factors such as market conditions, company performance, and industry trends. To understand the reasons behind these fluctuations, it is necessary to analyze the financial performance and operational challenges of PMCB, particularly in relation to its ongoing efforts to address an FDA clinical hold on its Investigational New Drug Application for pancreatic cancer treatment. Additionally, the company's investment in MyMD Pharmaceuticals, Inc. may also have an impact on its financial performance and EPS.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|PMCB|PMCB.O|PharmaCyte Biotech|2025 Q1|451.8518518518518|1.9|186|
|PMCB|PMCB.O|PharmaCyte Biotech|2025 Q2|-50|-0.39|186|
|PMCB|PMCB.O|PharmaCyte Biotech|2025 Q3|32.30769230769231|-0.44|186|